Sweden

11

Oct 2021

On September 20, 2021, Swedish Medical Technologies Product (MTP) Council announced ongoing horizon scanning for medical technology products used in obstructive lung diseases within the Orderly introduction framework. The Dental and Pharmaceutical Benefits Agency (TLV) initiated a theme survey, accepting suggestions until October 15, 2021. Read more

15

Sep 2021

On August 19, 2021, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the MammaPrint and EndoPredict tests for various reasons. Read more

08

Sep 2021

At the end of August 2021, the Swedish Dental and Pharmaceutical Benefits Agency (TLV) has initiated a theme survey on digital image diagnostics to identify new and innovative technology that may become important in Swedish healthcare. This could lead to potential inclusion of the technology in the Orderly introduction of medical technologies framework. The suggestions could be submitted no later than September 24, 2021. Read more

06

Aug 2021

In July 2021, the Dental and Pharmaceutical Benefits Agency released two completed health economic evaluations on the cost-effectiveness of the Oncotype DX and ProSigna tests. The evaluation was performed at the request of the Medical Technology Product (MTP) Council. The cost per quality-adjusted life-years for ProSigna is estimated to be 207,000 SEK compared to the stand-alone clinical pathology assessment. The analysis indicates that the use of Oncotype DX provides greater benefit than the alternative, also at a lower cost. Read more

19

Apr 2021

On April 09, 2021, the Swedish Medical Technologies Product (MTP) Council decided to add more technologies to the ongoing evaluation for self-monitoring of atrial fibrillation within the Orderly introduction framework, initiated in December 2020. MTP Council commissioned the Dental and Pharmaceutical Benefits Agency (TLV) to perform a health-economic evaluation of five products (Coala, KardiaMobile, CardioMem CM 100 XT, PhysioMem PM 100, Zenicor). MTP Council will then make recommendations to the regions on whether to adopt these technologies or not. Read more

10

Mar 2021

In the middle of February 2021, the Swedish Dental and Pharmaceutical Benefits Agency (TLV) launched the assessment on the following prognostic platforms for gene diagnostics in breast cancer: Oncotype DX, MammaPrint, ProSigna. The evaluation is planned for the spring of 2021. Read more

04

Mar 2021

The Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) systematically evaluates healthcare technologies and practices from medical, economic, ethical, and social standpoints. Currently, the SBU is working on assessments of treatment methods of gastrointestinal conditions, musculoskeletal disorders, pain treatment, medical aids, e-health technologies, and other topics. Read more

06

Jan 2021

In December 2020, Swedish Medical Technologies Product (MTP) Council decided to evaluate new technologies for self-monitoring of atrial fibrillation within the Orderly introduction framework. MTP Council commissioned the Swedish Dental and Pharmaceutical Benefits Agency (TLV) to perform a health-economic evaluation of Coala Heart Monitor Pro and KardiaMobile; however, other products may also be considered later. Read more

18

Dec 2020

In early December 2020, the Swedish National Board of Health and Welfare announced significant changes in the Swedish Classification of Health Care Measures (KVÅ) structure related to vascular surgery procedure codes. New Chapter V, “Operations on the aorta, peripheral vessels and lymphatic system,” will be introduced from January 2021, gathering all vascular surgical procedures previously located in several subchapters. Read more

14

Dec 2020

In November 2020, Stockholm Region issued a preliminary version of the prospective report for the management of health care up to 2040. The report raised the need for new ways of organizing health care in the Stockholm Region and outlined the increase of standardization and alignment trend, emerge of collaborative governance models, the increase of care structure complexity, etc. Read more

10

Dec 2020

On December 03, 2020, the Swedish Dental and Pharmaceutical Benefits Agency (TLV) published a report on its activities in health economic evaluations of medical technologies in 2020. The significant change is that since 2020 TLV has a permanent assignment to carry out horizon scanning and health economic evaluations of medical technology products as a part of the national orderly introduction framework. Read more

03

Dec 2020

The ultimate step in establishing reimbursement is achieved by making reimbursement applications to authorities. MTRC provides support with the development of reimbursement applications for a novel procedure code, change of diagnosis-related groups (DRGs) and establishing other payment mechanisms in the Nordic region and Russia. Read more